data + articles · 1 listed
newest 2001spec sheet8 rows
AGN-1135 is the racemic mixture of rasagiline (the R-(+)-enantiomer) and its much less active S-(-)-enantiomer, TVP-1022. It is a selective, irreversible monoamine oxidase B (MAO-B) inhibitor; nearly all of its MAO-B inhibiting activity comes from the rasagiline component, which was later developed and approved on its own for Parkinson's disease.
- Research precursor that led to rasagiline, an approved MAO-B inhibitor for Parkinson's disease
- Demonstrated selective, potent inhibition of MAO-B in early pharmacology studies
Overview
Essentially the unsplit precursor to rasagiline; researchers found the activity all lived in one enantiomer, so that one (rasagiline) went on to become the real drug.
Mechanism
AGN-1135 selectively and irreversibly inhibits monoamine oxidase B (MAO-B), the enzyme that breaks down . Virtually all of this inhibitory activity resides in the R-(+)- (rasagiline), which is several orders of magnitude more potent at MAO-B than the S-(-)-enantiomer (TVP-1022). Inhibiting MAO-B slows dopamine breakdown, which underlies its antiparkinsonian and studied neuroprotective effects.
receptor fingerprint
Monoamine oxidase B (MAO-B)Inhibitor
Safetyrisks and cautions, not medical advice
Because virtually all pharmacological activity resides in the rasagiline enantiomer, safety data for the racemate itself is limited; the rasagiline component's clinical safety profile (later developed separately) informed the field, including the general MAO-B inhibitor class caution around dietary tyramine at high doses and drug interactions with certain antidepressants.
Subjective profileweighing the evidence above
Of historical interest only. Its active half became rasagiline, an approved Parkinson's drug, so there is no reason to want the racemate; anyone after MAO-B inhibition should look at the drug that came out of it.
Resources
This entry is here for reference.
Research
1 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
What is AGN-1135 used for?
AGN-1135 itself was never marketed. It is historically important as the racemic research compound whose active enantiomer, rasagiline, became an approved Parkinson's disease medication.
How does AGN-1135 work?
It inhibits monoamine oxidase B, an enzyme that breaks down dopamine, effectively raising dopamine levels in the brain. Nearly all of this effect comes from its rasagiline component.
Is AGN-1135 well-researched?
Early pharmacology comparing its enantiomers is published, but as a standalone compound it was not carried through clinical development; research focus shifted to purified rasagiline.
Limitations of the evidence
- Not independently developed as a drug; safety data specific to the racemate is limited